国際個別化医療学会

In view of integrative cancer therapy, extension of survival terms with better and stable QOL are the object in this study. Under individual Evidence Based Medicine (EBM), AHCC and GCP have been used for Stage IV (M1) cancer of the lung and the breast. Long-term follow-up for 12 years from 1996 to 2009 has been carried out. A) Lung Cancer: Thirty-six M1 cases were enrolled. Cumulative survival rate of 1-year, 2-year and 3-year are 75.0%, 52.1% and 21.8%, respectively. A 4-year survival is 6.2% and no survival of 5 years. Median survival terms (MST) are 26.90 months. On QOL study, 41.7% of 36 M1 cases had better QOL in class A and B. B) Breast Cancer: Thirty-four M1 cases were enrolled. Twenty-two of 34 patients are dead and 12 patients are alive. Cumulative survival rate of 1-year, 2-year, 3-year, 4-year and 5-year are 100.0%, 84.4%, 68.3%, 47.9% and 36.8%, respectively. Median survival terms were 47.86 months. On QOL study, 67.7% of 34 M1 cases were in class A and B. Summary and Conclusion: Based on these results in comparing with the current cancer therapy, extension of survival terms with better QOL for M1 patients could be suggested by combination of AHCC and GCP in cancer therapy under individual EBM.

■Key words：Evidence Based Medicine (EBM), Standard EBM vs. Individual EBM, Active Hexose Correlated Compound (AHCC), Genistein Concentrated Polysaccharide (GCP), lung cancer, breast cancer
■連絡先　Takehito Miura, Amino Up Chemical Co., Ltd., 362-32 Shin-ei, Kiyota, Sapporo 004-0839, Japan
Tel: +81-11-889-2233　Fax: +81-11-889-2375　Presented in part at the 16th International Symposium of AHCC Research Association, Sapporo, Japan, July 27, 2008 and at the 10th International Society of Integrative Medicine, Tokyo, Japan, July 18, 2009.